Supplements for people on metformin
B12 monitoring (essential), CoQ10, magnesium, and the hypoglycemia-interaction list. Adjunct, not substitute, for your diabetes care plan.
The metformin-companion stack — rationale by ingredient
Vitamin B12 (methylcobalamin or hydroxocobalamin) — the non-negotiable one
Metformin reduces B12 absorption via interference with calcium-dependent terminal-ileum uptake. The 2024 ADA Standards of Care recommend periodic B12 monitoring in long-term metformin users, especially those with anaemia or neuropathy. Test serum B12 (and methylmalonic acid if borderline) every 1–2 years. Supplement at 500–1000 mcg/day if low or borderline. The B12 depletion effect is dose- and duration-dependent — patients on >1500 mg/day for >5 years are higher-risk.
Magnesium glycinate 300–400 mg elemental nightly
Low magnesium status is more common in type 2 diabetes and is associated with worse insulin sensitivity. The 2025 meta-analysis on magnesium and glycaemic control suggests modest improvement in HbA1c with supplementation in deficient patients. The glycinate form is the most GI-friendly. Particularly useful at night for sleep and muscle cramps.
CoQ10 (ubiquinol) 100–200 mg/day
Modest evidence that metformin reduces CoQ10 levels via mitochondrial-complex-I effects, though smaller than the statin effect. Worth considering in patients on metformin + statin combination or with documented exercise intolerance. Take with a fat-containing meal for absorption.
Omega-3 EPA/DHA 1.5–2 g/day
Foundational cardiovascular adjunct in diabetes. Reduces triglycerides and supports overall lipid management. Pair with a real cardiovascular care plan.
Vitamin D3 to a 25-OH-D of 30–50 ng/mL
Deficiency is more common in type 2 diabetes cohorts. Test first; supplement to the normal range. Routine high-dose empirical dosing is not appropriate.
Psyllium husk 5–10 g/day
Soluble fibre with FDA cholesterol claim and modest glycaemic effect (reduces postprandial glucose excursions). Take separately from metformin and other medications by 1–2 hours to avoid binding interactions.
Alpha-lipoic acid 600 mg/day (if neuropathy)
Best-evidenced supplement for diabetic peripheral neuropathy. Modest improvement in nerve-conduction studies and patient-reported pain at 600 mg/day. Use only if you have neuropathic symptoms; not a routine prophylactic.
Watch carefully or skip — hypoglycaemia stacking
- Berberine + metformin without monitoring — both lower glucose; combined effect can precipitate hypoglycaemia. If using, monitor glucose closely and discuss with your prescriber.
- Gymnema, bitter melon, cinnamon at therapeutic doses — additive glycaemic effect; same monitoring caution applies.
- Chromium "blood sugar support" stacks — modest effect in chromium-deficient diabetics, irrelevant in replete patients. Sub-therapeutic doses in most multi-vits.
- "Adrenal" or "cortisol" support botanicals alongside metformin — irrelevant to diabetes pathophysiology and add complexity.
- High-dose niacin — can worsen glycaemic control; ADA does not recommend routine use.
- Vitamin B6 >100 mg/day chronically — paradoxically can cause sensory neuropathy that mimics or worsens diabetic neuropathy.
Sources
- de Jager J, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181. PMID: 20488910
- American Diabetes Association. Standards of Medical Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1).
- Veronese N, et al. Magnesium and glycemic control: a 2025 meta-analysis. Nutrients. 2025;17(2):350.
- Liu Q, et al. Berberine and metformin combination on glycaemic control: a systematic review. Phytother Res. 2022;36(3):1116–1126. PMID: 34958160
- Ziegler D, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34(9):2054–2060. PMID: 21775755
- Aroda VR, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754–1761. PMID: 26900641